For the quarter ended December 2025, Cencora (COR) reported revenue of $85.93 billion, up 5.5% over the same period last year. EPS came in at $4.08, compared to $3.73 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $85.97 billion, representing a surprise of -0.04%. The company delivered an EPS surprise of +0.35%, with the consensus EPS estimate being $4.07.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Cencora performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Total U.S. Healthcare Solutions: $76.21 billion versus the four-analyst average estimate of $76.72 billion. The reported number represents a year-over-year change of +2.9%.
- Revenue- Total International Healthcare Solutions: $7.62 billion compared to the $7.45 billion average estimate based on four analysts. The reported number represents a change of +2.2% year over year.
- Revenue- Intersegment eliminations: $-32.73 million versus $-29.74 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +860.1% change.
View all Key Company Metrics for Cencora here>>>
Shares of Cencora have returned +4.5% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cencora, Inc. (COR): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
